NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · ADXS · USD
Stock price, earnings
Quote as of Feb 4, 2026, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Ayala Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ayala Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ayala Pharmaceuticals, Inc., a clinical-stage oncology firm, focuses on developing and commercializing small molecule therapies for individuals battling rare tumors and aggressive cancers. Its primary drug candidates currently in development include AL102, an oral gamma secretase inhibitor for desmoid tumors, and aspacytarabine (BST-236), an innovative, proprietary anti-metabolite designed for first-line treatment in acute myeloid leukemia patients who are considered unfit. The company is headquartered in Wilmington, Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $250.00K |
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$0.00$0.00 (0.0%)
America Great Health’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
CA$0.07-CA$0.01 (-7.14%)
Restart Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 51.85% below the high.
$0.05$0.00 (0.0%)
Agentix Corp.’s quoted price sits in the upper half of its reported 52-week range, 24.29% below the high.
$0.00$0.00 (0.0%)
Health Sciences Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
CA$0.32-CA$0.04 (-9.86%)
Grey Matters Health Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.44% below the high.
CA$0.01+CA$0.01 (+100.0%)
Appili Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
